Postmenopausal estrogen therapy and selected (less-often-considered) disease outcomes

Area of Science:

• Endocrinology
• Rheumatology
• Epidemiology

Background:

• Postmenopausal hormone therapy (HT) is widely used, but its effects on chronic conditions beyond traditional risks require investigation.
• Existing risk-benefit analyses often overlook associations with less common or non-cardiovascular chronic diseases.

Purpose of the Study:

• To review the association between postmenopausal estrogen therapy and chronic conditions not typically included in standard risk-benefit assessments.
• To synthesize evidence on HT's impact on conditions like autoimmune diseases, inflammatory disorders, and metabolic conditions.

Main Methods:

• A ten-year literature review (1989-1998) was conducted.
• Included case series and epidemiologic studies providing risk estimates and 95% confidence intervals.

Main Results:

• No consistent association was found between hormone therapy and osteoarthritis or rheumatoid arthritis.
• A nearly three-fold increased risk of systemic lupus erythematosus was observed after 2 or more years of HT.
• Increased risks for pancreatitis, asthma, and Raynaud's syndrome were suggested by single studies.
• Evidence for reduced diabetes mellitus risk was not compelling; effects on cataracts and migraine varied.
• Confirmed risks from clinical trials included gallbladder disease and venous thromboembolic disease.

Conclusions:

• The association between postmenopausal estrogen therapy and various chronic conditions requires further investigation.
• More comprehensive studies are needed to fully understand the long-term implications of hormone therapy on non-traditional health outcomes.